- Home
- CANG vs PGEN Comparison
CANG vs PGEN Comparison
Compare CANG & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- PGEN
- Stock Information
- Founded
- CANG 2010
- PGEN 1998
- Country
- CANG China
- PGEN United States
- Employees
- CANG N/A
- PGEN N/A
- Industry
- CANG Computer Software: Prepackaged Software
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- PGEN Health Care
- Exchange
- CANG Nasdaq
- PGEN Nasdaq
- Market Cap
- CANG 504.1M
- PGEN 577.0M
- IPO Year
- CANG 2018
- PGEN N/A
- Fundamental
- Price
- CANG $4.14
- PGEN $1.91
- Analyst Decision
- CANG
- PGEN Buy
- Analyst Count
- CANG 0
- PGEN 5
- Target Price
- CANG N/A
- PGEN $7.00
- AVG Volume (30 Days)
- CANG 358.6K
- PGEN 2.0M
- Earning Date
- CANG 03-10-2025
- PGEN 03-18-2025
- Dividend Yield
- CANG N/A
- PGEN N/A
- EPS Growth
- CANG N/A
- PGEN N/A
- EPS
- CANG 0.19
- PGEN N/A
- Revenue
- CANG $38,020,222.00
- PGEN $3,963,000.00
- Revenue This Year
- CANG $253.48
- PGEN N/A
- Revenue Next Year
- CANG N/A
- PGEN $402.12
- P/E Ratio
- CANG $22.60
- PGEN N/A
- Revenue Growth
- CANG N/A
- PGEN N/A
- 52 Week Low
- CANG $1.32
- PGEN $0.65
- 52 Week High
- CANG $9.66
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- CANG 38.49
- PGEN 68.55
- Support Level
- CANG $4.30
- PGEN $1.63
- Resistance Level
- CANG $5.22
- PGEN $2.17
- Average True Range (ATR)
- CANG 0.30
- PGEN 0.18
- MACD
- CANG -0.07
- PGEN 0.02
- Stochastic Oscillator
- CANG 3.57
- PGEN 71.74
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.